Snake antivenom for snake venom induced consumption coagulopathy

Background

Snake venom induced consumption coagulopathy is a major systemic eAect of envenoming. Observational studies suggestthat antivenom improves outcomes for venom induced consumption coagulopathy in some snakebites and not others.However, the eAectiveness of snake antivenom in all cases of venom induced consumption coagulopathy is controversial.

Objectives

To assess the eAect of snake antivenom as a treatment for venom induced consumption coagulopathy in people with snake bite.

Search methods

The search was done on 30 January 2015. We searched the Cochrane Injuries Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R), Embase Classic+Embase (OvidSP), three other sources, clinical trials registers, and we also screened reference lists.

Selection criteria

All completed, published or unpublished, randomised, controlled trials with a placebo or no treatment arm, where snake antivenom was administered for venom induced consumption coagulopathy in humans with snake bites.

Data collection and analysis

Two authors reviewed the identified trials and independently applied the selection criteria.

Main results

No studies met the inclusion criteria for this review.